Amgen's blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says
It’s been only about one year since Amgen’s KRAS-targeted NSCLC drug Lumakras has been marketed in the US, and already analysts are warning of waning sales for the blockbuster hopeful.
A report from SVB Securities on Monday said Lumakras’ Q2 sales didn’t come in as high as expected, with the analysts lowering US sales projections by 8%, from $60 million to $55 million, for the last quarter.
Also known as sotorasib, the drug won approval last May to treat types of non-small cell lung cancer with the KRAS G12C mutation, beating competitor Mirati Therapeutics to the regulatory finish line. At the time, analysts predicted the drug would secure more than $1 billion in peak sales, with a list price of $17,900 a month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.